{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:22:51Z","timestamp":1792106571020,"version":"4.4.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) is based on the results of robust clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the effectiveness and safety of BIC\/FTC\/TAF in treatment-na\u00efve (TN) and treatment-experienced (TE) people with HIV using available real-world cohort studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis of publications and communications identified via Boolean search in Medline, PubMed and Embase, and conference abstracts reporting retrospective real-world use of BIC\/FTC\/TAF, published until 31 January 2024. The primary endpoint was the proportion of TN and TE people with HIV with viral load (VL)\u200a&amp;lt;\u200a50\u2005copies\/mL at 48\u2005weeks while on treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 38 identified publications and conference abstracts, for the present analysis we included 12 publications (comprising 792 TN and 6732 TE individuals). For the three publications including 507 TN participants reporting the primary outcome, VL suppression was 97% [95% confidence intervals (CI): 89\u2013100]. For the nine publications including 4946 TE participants reporting the primary outcome, VL suppression was 95% (95% CI: 94\u201396), with suppression &amp;gt;93% in all studies. Total discontinuations at 48\u2005weeks in TE individuals were 3% (95% CI: 2\u20135), 1% (95% CI: 0\u20132) due to side effects. A total of four publications with 151 TE individuals with previous presence of M184V substitution were identified, reporting a suppression rate at 48\u2005weeks of 95% (95% CI: 88\u2013100).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Real-world studies demonstrate low discontinuation rates and high rates of virologic suppression in individuals treated with BIC\/FTC\/TAF, both TN and TE with and without previous detection of M184V substitution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkae138","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T15:42:42Z","timestamp":1714146162000},"page":"1775-1783","source":"Crossref","is-referenced-by-count":33,"title":["Effectiveness, safety and discontinuation rates of bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) in people with HIV using real-world data: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"79","author":[{"given":"Iv\u00e1n","family":"Chivite","sequence":"first","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Clinic- Fundacio de Recerca Clinic Barcelona\u2014Institut d'nvestigacions Biomediques August Pi i Sunyer, University of Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leire","family":"Berrocal","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Clinic- Fundacio de Recerca Clinic Barcelona\u2014Institut d'nvestigacions Biomediques August Pi i Sunyer, University of Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2614-6545","authenticated-orcid":false,"given":"Elisa","family":"de Lazzari","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Clinic- Fundacio de Recerca Clinic Barcelona\u2014Institut d'nvestigacions Biomediques August Pi i Sunyer, University of Barcelona , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soodabeh","family":"Navadeh","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc , Foster City , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Lluis-Ganella","sequence":"additional","affiliation":[{"name":"Gilead Sciences SL , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexy","family":"Inciarte","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Clinic- Fundacio de Recerca Clinic Barcelona\u2014Institut d'nvestigacions Biomediques August Pi i Sunyer, University of Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"de la Mora","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Clinic- Fundacio de Recerca Clinic Barcelona\u2014Institut d'nvestigacions Biomediques August Pi i Sunyer, University of Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0894-3711","authenticated-orcid":false,"given":"Ana","family":"Gonz\u00e1lez-Cord\u00f3n","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Clinic- Fundacio de Recerca Clinic Barcelona\u2014Institut d'nvestigacions Biomediques August Pi i Sunyer, University of Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mart\u00ednez-Rebollar","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Clinic- Fundacio de Recerca Clinic Barcelona\u2014Institut d'nvestigacions Biomediques August Pi i Sunyer, University of Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Laguno","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Clinic- Fundacio de Recerca Clinic Barcelona\u2014Institut d'nvestigacions Biomediques August Pi i Sunyer, University of Barcelona , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1996-4726","authenticated-orcid":false,"given":"Berta","family":"Torres","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Clinic- Fundacio de Recerca Clinic Barcelona\u2014Institut d'nvestigacions Biomediques August Pi i Sunyer, University of Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Blanco","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Clinic- Fundacio de Recerca Clinic Barcelona\u2014Institut d'nvestigacions Biomediques August Pi i Sunyer, University of Barcelona , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6911-8846","authenticated-orcid":false,"given":"Esteban","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Clinic- Fundacio de Recerca Clinic Barcelona\u2014Institut d'nvestigacions Biomediques August Pi i Sunyer, University of Barcelona , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Mallolas","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Clinic- Fundacio de Recerca Clinic Barcelona\u2014Institut d'nvestigacions Biomediques August Pi i Sunyer, University of Barcelona , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ambrosioni","sequence":"additional","affiliation":[{"name":"HIV Unit, Infectious Disease Service, Hospital Clinic- Fundacio de Recerca Clinic Barcelona\u2014Institut d'nvestigacions Biomediques August Pi i Sunyer, University of Barcelona , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"2024073123523156200_dkae138-B1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/COH.0000000000000527","article-title":"Current and future priorities for the development of optimal HIV drugs","volume":"14","author":"Vitoria","year":"2019","journal-title":"Curr Opin HIV AIDS"},{"key":"2024073123523156200_dkae138-B2","first-page":"115","article-title":"One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects","volume":"4","author":"Airoldi","year":"2010","journal-title":"Patient Prefer Adherence"},{"key":"2024073123523156200_dkae138-B3","doi-asserted-by":"crossref","first-page":"e0170661","DOI":"10.1371\/journal.pone.0170661","article-title":"Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy\u2014results from a large French multicenter cohort study","volume":"12","author":"Cotte","year":"2017","journal-title":"PLoS ONE"},{"key":"2024073123523156200_dkae138-B4","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1097\/QAD.0000000000000424","article-title":"Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir Remtricitabine\/lamivudine Refavirenz administered on a multiple tablet therapy","volume":"28","author":"Blanco","year":"2014","journal-title":"AIDS"},{"key":"2024073123523156200_dkae138-B5","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40265-020-01379-9","article-title":"HIV-1 integrase inhibitors: a comparative review of efficacy and safety","volume":"80","author":"Scarsi","year":"2020","journal-title":"Drugs"},{"key":"2024073123523156200_dkae138-B6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"2024073123523156200_dkae138-B7","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/hiv.13542","article-title":"Major revision version 12.0 of the European AIDS Clinical Society Guidelines 2023","volume":"24","author":"Ambrosioni","year":"2023","journal-title":"HIV Med"},{"key":"2024073123523156200_dkae138-B8","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ijantimicag.2019.08.008","article-title":"Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors","volume":"54","author":"Yang","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2024073123523156200_dkae138-B9","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380\u20131490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2024073123523156200_dkae138-B10","doi-asserted-by":"crossref","first-page":"E485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus","volume":"73","author":"Sax","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024073123523156200_dkae138-B11","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, Abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"2024073123523156200_dkae138-B12","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus Abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"2024073123523156200_dkae138-B13","doi-asserted-by":"crossref","first-page":"180080","DOI":"10.1183\/16000617.0080-2018","article-title":"Randomised controlled trials and real-life studies: two answers for one question","volume":"27","author":"Harari","year":"2018","journal-title":"Eur Respir Rev"},{"key":"2024073123523156200_dkae138-B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofaa285","article-title":"Short-term adverse events with BIC\/FTC\/TAF: postmarketing study","volume":"7","author":"Hayes","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2024073123523156200_dkae138-B15","doi-asserted-by":"crossref","first-page":"512","DOI":"10.18683\/germs.2021.1286","article-title":"Treatment initiation or switch to BIC\/FTC\/TAF-real-world safety and efficacy data from two HIV centers in Romania","volume":"11","author":"S\u0103ndulescu","year":"2021","journal-title":"Germs"},{"key":"2024073123523156200_dkae138-B16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jgar.2022.06.027","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice","volume":"30","author":"Armenia","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"2024073123523156200_dkae138-B17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.37201\/req\/148.2020","article-title":"Effectiveness, safety, and economic impact of the bictegravir\/emtricitabine\/tenofovir alafenamide regimen in real clinical practice cohort of HIV-1 infected adult patients","volume":"34","author":"Guti\u00e9rrez-Lorenzo","year":"2021","journal-title":"Rev Esp Quimioter"},{"key":"2024073123523156200_dkae138-B18","doi-asserted-by":"crossref","first-page":"e27330","DOI":"10.1097\/MD.0000000000027330","article-title":"Real-world efficacy and safety of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in older people living with HIV","volume":"100","author":"Rolle","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2024073123523156200_dkae138-B19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.36469\/jheor.2021.2435","article-title":"Weight change and predictors of weight change among patients initiated on darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide or bictegravir\/emtricitabine\/tenofovir alafenamide: a real-world retrospective study","volume":"8","author":"Emond","year":"2021","journal-title":"J Health Econ Outcomes Res"},{"key":"2024073123523156200_dkae138-B20","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/jac\/dkab481","article-title":"Real-life experience with bictegravir\/emtricitabine\/tenofovir alafenamide in a large reference clinical centre","volume":"77","author":"Ambrosioni","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2024073123523156200_dkae138-B21","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/diagnostics12010076","article-title":"Switching to a bictegravir single tablet regimen in elderly people living with HIV-1: data analysis from the BICTEL cohort","volume":"12","author":"Lazzaro","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"2024073123523156200_dkae138-B22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3851\/IMP3351","article-title":"Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine\/tenofovir alafenamide in clinical practice","volume":"25","author":"Hoffmann","year":"2021","journal-title":"Antivir Ther"},{"key":"2024073123523156200_dkae138-B23","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1097\/QAD.0000000000003311","article-title":"Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir\/emtricitabine\/tenofovir alafenamide in treatment experience patients","volume":"36","author":"Mic\u00e1n","year":"2022","journal-title":"AIDS"},{"key":"2024073123523156200_dkae138-B24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijid.2022.11.012","article-title":"Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N\/R mutation","volume":"126","author":"Tsai","year":"2023","journal-title":"Int J Infect Dis"},{"key":"2024073123523156200_dkae138-B25","author":"Mallolas"},{"key":"2024073123523156200_dkae138-B26","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.2147\/IDR.S331647","article-title":"Outcomes after switching to BIC\/FTC\/TAF in patients with virological failure to protease inhibitors or non-nucleoside reverse transcriptase inhibitors: a real-world cohort study","volume":"14","author":"Chang","year":"2021","journal-title":"Infect Drug Resist"},{"key":"2024073123523156200_dkae138-B27","doi-asserted-by":"crossref","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"18","author":"Page","year":"2021","journal-title":"PLoS Med"},{"key":"2024073123523156200_dkae138-B28","author":"Wells"},{"key":"2024073123523156200_dkae138-B29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2024073123523156200_dkae138-B30","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"2024073123523156200_dkae138-B31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health"},{"key":"2024073123523156200_dkae138-B32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","article-title":"A new improved graphical and quantitative method for detecting bias in meta-analysis","volume":"16","author":"Furuya-Kanamori","year":"2018","journal-title":"Int J Evid Based Healthc"},{"key":"2024073123523156200_dkae138-B33"},{"key":"2024073123523156200_dkae138-B34","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1097\/CM9.0000000000002907","article-title":"Efficacy and safety profiles of dolutegravir plus lamivudine vs. bictegravir\/emtricitabine\/tenofovir alafenamide in therapy-na\u00efve adults with HIV-1","volume":"136","author":"Wei","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"2024073123523156200_dkae138-B35","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/hiv.13493","article-title":"Efficacy, durability, and tolerability of bictegravir\/emtricitabine\/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium","volume":"24","author":"Nasreddine","year":"2023","journal-title":"HIV Med"},{"key":"2024073123523156200_dkae138-B36","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1007\/s40121-023-00879-x","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide versus dolutegravir plus lamivudine for switch therapy in patients with HIV-1 infection: a real-world cohort study","volume":"12","author":"Gan","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2024073123523156200_dkae138-B37","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3390\/v15081727","article-title":"Predicting factors of plasma HIV RNA undetectability after switching to co-formulated bictegravir, emtricitabine, and tenofovir alafenamide in experienced HIV-1 patients: a multicenter study","volume":"15","author":"Basso","year":"2023","journal-title":"Viruses"},{"key":"2024073123523156200_dkae138-B38","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/jac\/dkae011","article-title":"Real-life data of immune recovery using bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48\u201396weeks of RETROBIC study","volume":"79","author":"Troya","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2024073123523156200_dkae138-B39","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/QAI.0000000000002454","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) from dolutegravir (DTG)+F\/TAF or DTG\u200a+\u200aF\/tenofovir disoproxil fumarate (TDF) in the presence of pre-existing NRTI resistance","volume":"85","author":"Acosta","year":"2020","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/8\/1775\/58689053\/dkae138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/8\/1775\/58689053\/dkae138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T02:16:12Z","timestamp":1722478572000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/8\/1775\/7675998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,5,17]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae138","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,5,17]]}}}